John Otrompke

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

While BRCA status continues to be a predictive indicator of response to rucaparib for patients with ovarian cancer, loss of genomic heterozygosity was shown to also be an effective biomarker for predicting outcomes.

A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.

A device using tumor treating fields that was administered to patients with unresectable pancreatic cancer showed early signs of tolerability and safety when in combination with gemcitabine in the frontline setting.

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.

Results of a recent study show that patients with low-risk thyroid-related microcarcinoma who choose to undergo immediate surgery are at higher risk for adverse events and unnecessary risk compared with those who decide on active surveillance.

An emerging vaccine strategy, of TG4010 immunotherapy and first-line chemotherapy, that could target a potential new biomarker in patients with advanced non-small cell lung cancer (NSCLC) has successfully reached a phase III clinical trial, researchers noted.